Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLX4 structure-specific endonuclease subunit (SLX4)
- Target
- SLX4
- Molecular classification
- Enzyme, DNA repair scaffold protein
01
Overview
SLX4 is a scaffold protein that forms a structure-specific endonuclease complex with SLX1 to process branched DNA substrates during DNA repair. The SLX1–SLX4 complex cleaves structures like Holliday junctions, 5′-flaps, and stalled replication forks to maintain genome stability. SLX4 is required for efficient DNA cleavage and interacts with numerous DNA repair proteins, including MUS81–EME1, XPF–ERCC1, and components of the Fanconi anemia pathway. Mutations in SLX4 are implicated in cancer predisposition and Fanconi anemia (as FANCP)[3][1][2].
- Other names
- SLX4BTBD12FANCPStructure-specific endonuclease SLX4 subunit
02
Mechanism of action
Drugs targeting SLX4 would generally act by modulating DNA repair processes, particularly those dependent on structure-specific endonucleases, or by synthetic lethality in cancer therapy
03
Biological functions
DNA damage repairResolution of Holliday junctionsProcessing of stalled replication forksMaintenance of genome stabilityInterstrand crosslink repairTelomere maintenanceNucleotide excision repair
04
Disease associations
CancerFanconi anemiaOther genome instability syndromes
05
Safety considerations
Loss of SLX4 function can cause genome instability, hypersensitivity to DNA-damaging agentsMutations may predispose to cancer, bone marrow failure (Fanconi anemia)
06
Interacting drugs
No approved drugs directly target SLX4, but DNA repair inhibitors (e.g., PARP inhibitors) may have indirect effects due to pathway overlap
07
Biomarkers
SLX4 mutations (biomarker for Fanconi anemia subtype)SLX4 protein levels (potentially predictive of DNA repair capacity and therapeutic response in cancer, though not yet an approved clinical biomarker)
Beyond the preview
Go deeper on SLX4 structure-specific endonuclease subunit (SLX4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLX4 structure-specific endonuclease subunit (SLX4).